Steven Woloshin

Generating author description...

All published works

Action	Title	Year	Authors
+ PDF Chat	Communication of Survival Data in US Food and Drug Administration–Approved Labeling of Cancer Drugs	2021	Huseyin Naci Xiaodong Guan Steven Woloshin Ziyue Xu Anita K. Wagner
+	Policy makers must act on incomplete evidence in responding to COVID-19	2020	Karla Soares‐Weiser Toby J Lasserson Karsten Juhl Jørgensen Steven Woloshin Lisa Bero Michael D. Brown Baruch Fischhoff
+ PDF Chat	Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis	2018	Joshua D. Wallach Alexander C. Egilman Joseph S. Ross Steven Woloshin Lisa M. Schwartz
+ PDF Chat	Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis	2018	Joshua D. Wallach Alexander C. Egilman Sanket S. Dhruva Margaret E. McCarthy Jennifer Miller Steven Woloshin Lisa M. Schwartz Joseph S. Ross
+ PDF Chat	Characteristics of Interim Publications of Randomized Clinical Trials and Comparison With Final Publications	2018	Steven Woloshin Lisa M. Schwartz Pamela J. Bagley Heather B. Blunt Brian White
+ PDF Chat	ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials	2016	Lisa M. Schwartz Steven Woloshin Eugene Zheng Tony Tse Deborah A. Zarin
+ PDF Chat	Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review	2010	Gloria Córdoba Lisa Schwartz Steven Woloshin Hyun W. Bae Peter C Gøtzsche
+ PDF Chat	Quantitative Literacy Assessments: An Introduction to Testing Tests	2009	Dorothy Wallace Kim Rheinlander Steven Woloshin Lisa Schwartz
+ PDF Chat	Helping Doctors and Patients Make Sense of Health Statistics	2007	Gerd Gigerenzer Wolfgang Gaissmaier Elke Kurz‐Milcke Lisa M. Schwartz Steven Woloshin

Common Coauthors

Coauthor	Papers Together
Lisa M. Schwartz	5
Joseph S. Ross	2
Joshua D. Wallach	2
Alexander C. Egilman	2
Lisa Schwartz	2
Eugene Zheng	1
Sanket S. Dhruva	1
Anita K. Wagner	1
Lisa Bero	1
Jennifer Miller	1
Pamela J. Bagley	1
Kim Rheinlander	1
Michael D. Brown	1
Huseyin Naci	1
Deborah A. Zarin	1
Ziyue Xu	1
Karsten Juhl Jørgensen	1
Toby J Lasserson	1
Hyun W. Bae	1
Heather B. Blunt	1
Baruch Fischhoff	1
Brian White	1
Wolfgang Gaissmaier	1
Dorothy Wallace	1
Xiaodong Guan	1
Tony Tse	1
Margaret E. McCarthy	1
Karla Soares‐Weiser	1
Gloria Córdoba	1
Elke Kurz‐Milcke	1
Gerd Gigerenzer	1
Peter C Gøtzsche	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials	2004	An‐Wen Chan Asbjørn Hróbjartsson Mette T. Haahr Peter C Gøtzsche Douglas G. Altman	2
+	A Lifecycle Approach to the Evaluation of FDA Approval Methods and Regulatory Actions	2012	Bruce M. Psaty Eric M. Meslin Alasdair Breckenridge	2
+ PDF Chat	Communicating Statistical Information	2000	Ulrich Hoffrage Samuel C. Lindsey Ralph Hertwig Gerd Gigerenzer	1
+	Outcomes and endpoints in trials of cancer treatment: the past, present, and future	2014	Michelle Wilson Katherine Karakasis Amit M. Oza	1
+	Registering Clinical Trial Results	2010	James Dabney Miller	1
+	Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns	2007	Ignacio Ferreira‐González Gaietà Permanyer-Miralda Jason W. Busse Dianne Bryant Víctor M. Montori Pablo Alonso‐Coello Stephen D. Walter Gordon Guyatt	1
+	Measured Enthusiasm: Does the Method of Reporting Trial Results Alter Perceptions of Therapeutic Effectiveness?	1992	C. David Naylor Erluo Chen Bradley H. Strauss	1
+ PDF Chat	Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis	2008	Kirby Lee Peter Bacchetti Ida Sim	1
+	THE CALCULUS TRAP*	2002	Jane Korey	1
+ PDF Chat	Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications–a cross-sectional study	2013	Amy Earley Joseph Lau Katrin Uhlig	1
+ PDF Chat	Children can solve Bayesian problems: the role of representation in mental computation	2005	Liqi Zhu Gerd Gigerenzer	1
+	The Emergence of Probability.	1978	Terrence L. Fine Ian Hacking	1
+	When doctors meet numbers	1981	Donald M. Berwick Harvey V. Fineberg Milton C. Weinstein	1
+	Reflections on statistics - Learning, teaching and assessment in grades k-12	2000	David W. Green	1
+	Composite End Points in Randomized Trials	2010	George Tomlinson Allan S. Detsky	1
+	Composite Outcomes in Randomized Trials	2003	Nick Freemantle Melanie Calvert John Wood Joanne Eastaugh Carl Griffin	1
+ PDF Chat	Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials	2007	Ignacio Ferreira‐González Gaiet Permanyer-Miralda Antònia Domingo‐Salvany Jason W. Busse Diane Heels‐Ansdell Víctor M. Montori Elie A. Akl Dianne Bryant Pablo Alonso‐Coello Jordi Alonso	1
+ PDF Chat	Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications	2014	Daniel M. Hartung Deborah A. Zarin Jeanne‐Marie Guise Marian McDonagh Robin Paynter Mark Helfand	1
+	Interim results in clinical trials: Do we need to keep all interim randomised clinical trial results confidential?	2014	Richard Stephens Ruth E. Langley P. Mulvenna Matthew Nankivell Andy Vail Mahesh Parmar	1
+ PDF Chat	Believability of relative risks and odds ratios in abstracts: cross sectional study	2006	Peter C Gøtzsche	1
+ PDF Chat	Why does framing influence judgment?	2003	Gerd Gigerenzer	1
+	Teaching Bayesian reasoning: an evaluation of a classroom tutorial for medical students	2002	Stephanie Kurzenhäuser Ulrich Hoffrage	1
+	Risikokommunikation bei Brustkrebsfrüherkennung und Hormonersatztherapie	2003	Ulrich Hoffrage	1
+	How Patients' Preferences for Risk Information Influence Treatment Choice in a Case of High Risk and High Therapeutic Uncertainty	1999	Dennis J. Mazur David H. Hickam Marcus D. Mazur	1
+	Combined endpoints: can we use them?	2002	Jacobus Lubsen Bridget‐Anne Kirwan	1
+	Reporting of Noninferiority Trials in ClinicalTrials.gov and Corresponding Publications	2015	Anand Gopal Nihar R. Desai Tony Tse Joseph S. Ross	1
+	In search of the benefits of learning Latin.	2003	Ludwig Haag Elsbeth Stern	1
+ PDF Chat	Teaching Bayesian reasoning in less than two hours.	2001	Peter Sedlmeier Gerd Gigerenzer	1
+	What statistics should we teach medical undergraduates and graduates?	1990	Davi D. R. Appleton	1
+	How Students Learn Statistics Revisited: A Current Review of Research on Teaching and Learning Statistics	2007	Joan Garfield Dani Ben‐Zvi	1
+	Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials	2002	Jim Nuovo	1
+ PDF Chat	Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012	2014	Nicholas S. Downing Jenerius A. Aminawung Nilay D. Shah Harlan M. Krumholz Joseph S. Ross	1
+	Presenting Risk Information A Review of the Effects of Framing and other Manipulations on Patient Outcomes	2001	A Edwards Glyn Elwyn Judith Covey E Matthews Roisin Pill	1
+ PDF Chat	Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation	2008	Kristin L. Rising Peter Bacchetti Lisa Bero	1
+ PDF Chat	New Pedagogy and New Content: The Case of Statistics	1997	David S. Moore	1
+ PDF Chat	Overcoming difficulties in Bayesian reasoning: A reply to Lewis and Keren (1999) and Mellers and McGraw (1999).	1999	Gerd Gigerenzer Ulrich Hoffrage	1
+	Classical probability in the Enlightenment	1989		1
+	Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects<subtitle>Systematic Review and Meta-regression Analysis</subtitle>	2010	Dirk Bassler Matthias Briel Víctor M. Montori Melanie A. Lane Paul Glasziou Qi Zhou Diane Heels‐Ansdell Stephen D. Walter Gordon Guyatt David N. Flynn	1
+	The Child's Understanding of Number	1979	Karen C. Fuson Rochel Gelman C. R. Gallistel	1
+	Schulung frühen stochastischen Denkens von Kindern	2005	Laura Martignon Christoph Wassner	1
+	The Emergence of Probability.	1976	Glenn Shafer Ian Hacking	1
+ PDF Chat	Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research	2016	Hao Wang Gary L. Rosner Steven N. Goodman	1
+ PDF Chat	Publishing interim results of randomised clinical trials in peer-reviewed journals	2016	Nicholas Counsell Despina Biri Joanna Fraczek Allan Hackshaw	1
+	Enhancing Transparency at the US Food and Drug Administration	2017	Joshua M. Sharfstein Michael Stebbins	1
+ PDF Chat	Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval	2017	Huseyin Naci Olivier J. Wouters Radhika Gupta John P. A. Ioannidis	1
+ PDF Chat	Association of the FDA Amendment Act with trial registration, publication, and outcome reporting	2017	Adam Phillips Nihar R. Desai Harlan M. Krumholz Constance X. Zou Jennifer Miller Joseph S. Ross	1
+	Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration	2017	Huseyin Naci Katelyn R. Smalley Aaron S. Kesselheim	1
+ PDF Chat	FDA Oversight of Postmarketing Studies	2017	Mwango Kashoki Cathryn Lee Peter Stein	1
+ PDF Chat	Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies	2017	Jennifer Miller Marc Wilenzick Nolan Ritcey Joseph S. Ross Michelle M. Mello	1
+	The Child's Understanding of Number	1979	U. A. Easley Rochel Gelman C. H. Galistell	1